Behcet's syndrome pathophysiology and potential therapeutic targets

被引:51
|
作者
Emmi, Giacomo [1 ]
Silvestri, Elena [1 ,2 ,3 ]
Squatrito, Danilo [2 ,3 ]
D'Elios, Mario Milco [1 ,2 ,3 ]
Ciucciarelli, Lucia [1 ]
Prisco, Domenico [1 ,2 ,3 ]
Emmi, Lorenzo [2 ,3 ]
机构
[1] Univ Florence, Dept Expt & Clin Med, I-50134 Florence, Italy
[2] AOU Careggi, SOD Patol Med, Ctr Autoimmune Syst Dis, Behcet Ctr, Florence, Italy
[3] AOU Careggi, Lupus Clin, Florence, Italy
关键词
Behcet syndrome pathophysiology; Behcet treatment; Biologic therapy; Anti-TNF-alpha; IL-1 blocking agents; GENOME-WIDE ASSOCIATION; TUMOR-NECROSIS-FACTOR; V-GAMMA-9/V-DELTA-2; T-LYMPHOCYTES; FAMILIAL MEDITERRANEAN FEVER; INTERFERON ALPHA-2A; STREPTOCOCCUS-SANGUIS; DOUBLE-BLIND; TNF FAMILY; DISEASE; UVEITIS;
D O I
10.1007/s11739-013-1036-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Behcet syndrome is a systemic inflammatory disorder characterized by multiorgan involvement such as oral and genital ulcers, uveitis, skin lesions as well as by less frequent, but often more severe, central nervous system and vascular manifestations. The pathogenetic mechanisms are still incompletely known; however the interaction between a specific genetic background and environmental or infectious factors certainly contributes to the immune dysregulation that characterizes this disease. The discovery of new immunological pathways in Behcet syndrome pathogenesis may help us to set up new treatments. In this review, we will focus our attention on the possible mechanisms underlying Behcet syndrome pathogenesis and their potential role as novel therapeutic targets.
引用
收藏
页码:257 / 265
页数:9
相关论文
共 50 条
  • [11] Cardiorenal syndrome: pathophysiology and potential targets for clinical management
    Hatamizadeh, Parta
    Fonarow, Gregg C.
    Budoff, Matthew J.
    Darabian, Sirous
    Kovesdy, Csaba P.
    Kalantar-Zadeh, Kamyar
    NATURE REVIEWS NEPHROLOGY, 2013, 9 (02) : 99 - 111
  • [12] New therapeutic solutions for Behcet's syndrome
    Vitale, Antonio
    Rigante, Donato
    Lopalco, Giuseppe
    Emmi, Giacomo
    Bianco, Maria Teresa
    Galeazzi, Mauro
    Iannone, Florenzo
    Cantarini, Luca
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (07) : 827 - 840
  • [13] Intestinal Behcet's disease: Epidemiology, pathophysiology and potential of mesalazine
    Kitauchi, S
    Nishi, S
    Nishioka, S
    BIODRUGS, 2000, 13 (06) : 409 - 413
  • [14] Potential New Therapeutic Options for Involvement of Central Nervous System in Behcet's Disease (Neuro-Behcet's Syndrome)
    Hirohata, Shunsei
    CURRENT RHEUMATOLOGY REVIEWS, 2007, 3 (04) : 297 - 303
  • [15] Purinergic pathophysiology and therapeutic targets
    Burnstock, Geoff
    PURINERGIC SIGNALLING, 2012, 8 (01) : 114 - 114
  • [16] Pathophysiology of Behcet's disease
    Amoura, Z.
    Guillaume, M.
    Caillat-Zucman, S.
    Wechsler, B.
    Piette, J. -C.
    REVUE DE MEDECINE INTERNE, 2006, 27 (11): : 843 - 853
  • [17] Pathophysiology of Behcet's disease
    Houman, M. H.
    Feki, N. Bel
    REVUE DE MEDECINE INTERNE, 2014, 35 (02): : 90 - 96
  • [18] Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets
    Zegallai, Hana M.
    Hatch, Grant M.
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2021, 476 (03) : 1605 - 1629
  • [19] Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets
    Yu, Kangjie
    Rohr, Joseph
    Liu, Yang
    Li, Mingyang
    Xu, Junpeng
    Wang, Kaijing
    Chai, Jia
    Zhao, Danhui
    Liu, Yixiong
    Ma, Jing
    Fan, Linni
    Wang, Zhe
    Guo, Shuangping
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (04)
  • [20] Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets
    Hana M. Zegallai
    Grant M. Hatch
    Molecular and Cellular Biochemistry, 2021, 476 : 1605 - 1629